These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 23884439)
1. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439 [TBL] [Abstract][Full Text] [Related]
2. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Matsubara J; Nishina T; Yamada Y; Moriwaki T; Shimoda T; Kajiwara T; Nakajima TE; Kato K; Hamaguchi T; Shimada Y; Okayama Y; Oka T; Shirao K Br J Cancer; 2008 Feb; 98(4):832-9. PubMed ID: 18231104 [TBL] [Abstract][Full Text] [Related]
3. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002). Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170 [TBL] [Abstract][Full Text] [Related]
4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A; Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685 [TBL] [Abstract][Full Text] [Related]
5. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295 [TBL] [Abstract][Full Text] [Related]
6. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology]. Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702 [TBL] [Abstract][Full Text] [Related]
7. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Sasako M; Terashima M; Ichikawa W; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H Gastric Cancer; 2015 Jul; 18(3):538-48. PubMed ID: 25112781 [TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Koopman M; Venderbosch S; van Tinteren H; Ligtenberg MJ; Nagtegaal I; Van Krieken JH; Punt CJ Eur J Cancer; 2009 Jul; 45(11):1999-2006. PubMed ID: 19457654 [TBL] [Abstract][Full Text] [Related]
9. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Uchida K; Hayashi K; Kuramochi H; Takasaki K Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849 [TBL] [Abstract][Full Text] [Related]
10. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501 [TBL] [Abstract][Full Text] [Related]
11. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592 [TBL] [Abstract][Full Text] [Related]
12. A predictive factor for the response to S-1 plus cisplatin in gastric cancer. Miyazaki I; Kawai T; Harada Y; Moriyasu F World J Gastroenterol; 2010 Sep; 16(36):4575-82. PubMed ID: 20857529 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051 [TBL] [Abstract][Full Text] [Related]
14. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. Takashima A; Boku N; Kato K; Nakamura K; Mizusawa J; Fukuda H; Shirao K; Shimada Y; Ohtsu A Gastric Cancer; 2014; 17(3):522-8. PubMed ID: 24162387 [TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540 [TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Ichikawa W; Takahashi T; Suto K; Yamashita T; Nihei Z; Shirota Y; Shimizu M; Sasaki Y; Hirayama R Br J Cancer; 2004 Oct; 91(7):1245-50. PubMed ID: 15354215 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514 [TBL] [Abstract][Full Text] [Related]
19. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Metzger R; Leichman CG; Danenberg KD; Danenberg PV; Lenz HJ; Hayashi K; Groshen S; Salonga D; Cohen H; Laine L; Crookes P; Silberman H; Baranda J; Konda B; Leichman L J Clin Oncol; 1998 Jan; 16(1):309-16. PubMed ID: 9440758 [TBL] [Abstract][Full Text] [Related]
20. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]